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The availability of random peptide libraries displayed on bacteriophage (RPL) has provided a powerful tool for selecting sequences
that mimic binding properties of natural antigen epitopes (mimotopes). These mimotopes can be used for vaccine design,
drug development, and diagnostic assays. Several mimotopes have been shown to induce production of antibodies against
the natural antigen. We have previously identified four dengue virus mimotopes from a phage-displayed peptide library using
antidengue 3 human sera. Three of them showed similarity in their amino acid sequences with the NS4b proteins of dengue.
Few studies have examined the role of NS4b proteins in the antibody response to dengue virus infection. A multiple antigen
peptide (MAP) system was chemically synthesized containing this mimotope (NS4b MAP), and BALB/c mice were immunized
to evaluate its immunogenicity. Antipeptide responses were induced and recognised DENV-3 infected cells as determined by
immunofluorescence. The high levels of the IgG2a subtype against NS4bMAP suggest the induction of a Th1-like response. Our
findings suggest that the NS4b mimotope might be a useful tool for the development of multiepitope diagnostic assays, dengue
virus vaccine design, and pathogenesis studies.
1. Introduction
Dengue is currently one of the most important mosquito-
borne viral diseases of humansworldwide. Four viruses (den-
gue virus 1–4) belonging to the family Flaviviridae, genus
Flavivirus, are responsible for this disease. Classically, two
main syndromes are recognized: dengue fever and dengue
hemorrhagic fever/dengue shock syndrome (DHF)/(DSS).
The WHO classification of DHF/DSS was reviewed recently,
and a new classification (dengue and severe dengue) has been
proposed [1].
The dengue virus genome is composed of a linear, single
stranded, and positive sense RNA molecule which is trans-
lated into a single polyprotein precursor comprising only one
ORF. The polyprotein is cotranslationally processed by host
and virus specific proteases to 10 individual proteins: three
structural proteins (capsid (C), premembrane (prM), and
envelope (E)) and seven nonstructural (NS) proteins (NS1, 2a,
2b, 3, 4a, 4b, and 5) [2].
The identification and characterization of B-cell epitopes
fromdengue virus is highly relevant for understanding events
related to natural infection, immunopathology, and for vac-
cines or diagnostic applications. B-cell epitopes have been
reported from several dengue virus proteins, the greatest
number being derived from E glycoprotein, followed by the
nonstructural protein NS1 [3–5]. Although the C and prM/M
proteins are conserved structural antigens, fewB-cell epitopes
have been defined from these proteins [6, 7]. Linear epitopes
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from the small hydrophobic nonstructural NS4a and NS3
proteins have also been identified [6, 8, 9].
Very little is known concerning the antigenic determi-
nants of NS4b protein; it is involved in inhibition of the inter-
feron response in host cells [10] and may also serve as an
anchor for the viral replication complex to the endoplasmic
reticulum membrane. Recently, it has been reported that
dengue virus NS4b is primarily responsible for the induction
of immunomediators such as IL6, IL-8, IP-10, TNF𝛼, and
IFN𝛾 [11] and is a target for inhibition of dengue virus infec-
tion [12]. However the role of NS4b in the immune response
has been poorly studied due to its transmembrane nature and
the absence of an external surface domain.
Phage display has proven to be a powerful and economic
technique for epitope identification and has been widely used
in epitope mapping of Flavivirus [9]. We have previously
identified four dengue mimotopes using a from a phage-dis-
played peptide library and showed similarity in their amino
acid sequences with NS3 and NS4b nonstructural proteins of
dengue virus [8]. The role of NS4b in the immune response
has been poorly studied, but consistent antibody responses to
NS4b in serum samples from dengue have been reported
[13]. In order to determine whether NS4b can induce an
antibody response against dengue virus, we synthesized a
multiple antigen peptide system (MAP) containing the NS4b
mimotope and tested its ability to stimulate an immune
response. The knowledge derived from this study will help
elucidate whether NS4b is involved in humoral immunity
during the viral infection cycle.
2. Materials and Methods
2.1. Synthetic Peptides. A peptide construct was prepared in
the synthetic peptide laboratory at the Center for Genetic
Engineering and Biotechnology (CIGB, Havana City). Syn-
thesis was performed manually on Fmoc-AM-MBHA resin
by a stepwise solid-phase procedure using the Fmoc/tBu
strategy and containedNS4bmimotope: FERVPGEV [8].The
peptide was characterized by reversed phase high-perform-
ance liquid chromatography and electrospray ionizationmass
spectrometry. A four-armedMAP based on the NS4b mimo-
tope sequence was synthesized (Figure 1) and named as NS4b
MAP.
Additional peptides to be used as controls in all assays
were also synthesized. A positive control peptide (E, mimetic
of envelope dengue protein), was derived from screening a
phage-displayed peptide library with the H3/6 monoclonal
antibody [14]; a negative control peptide, MAP46-56, con-
taining two HAV mimotopes (46 and 56) was previously
described by Larralde et al. [15].
2.2. Polyclonal Antibodies. NS4b-specific polyclonal rabbit
antiserum, raised against a GST-NS4b 127–170 aa fusion
protein, was a generous gift from Dr. Ralf Bartenschlager,
Department ofMolecular Virology, University of Heidelberg,
Germany [10].
2.3. Purification of Phages Displaying Peptide Mimetic NS4b.
Phages clones (Ph) 2, 15, and 35 [8] and M13K07 phage
NS4b
NS4b
NS4b FERVPGEV
NS4b S
CK K
S
C
NS4b
(𝛽) A (𝛽) A
Figure 1: Chemical structure of MAP of NS4b mimotope sequence.
(wild type control) were amplified in liquid cultures of E. coli
TG1 and purified by precipitation with polyethylene glycol
(PEG8000)/NaCL. Each purified phage clone was tittered,
and its concentrationwas adjusted to 1012UFC/mL for ELISA
assays [15].
2.4. Anti-NS4b Polyclonal Antibody ELISA. Recognition of
phage clones and peptide constructs by dengue anti-NS4b
polyclonal antiserum was evaluated by an indirect ELISA.
Multiwell plates (Nunc Maxisorp F8, Life Technologies Lim-
ited, Paisley, UK) were coated with purified phages (108 CFU/
well) and peptides (5 𝜇g/mL) diluted in 0.05M sodium
carbonate buffer pH 9.6 (coating buffer), during 18 h at 4∘C.
Plates were washed thrice with phosphate buffered saline in
0.05% Tween 20 (PBS/T) and blocked with skimmed milk
(3%w/v) in PBS/T (blocking solution). Rabbit anti-NS4b
polyclonal antiserum diluted in blocking solution (1 : 500,
100 𝜇L per well) was added to the plates for 1 h at 37∘C.
After repeating the washes, bound antibodies were detect-
ed with HRP-conjugated goat anti-rabbit IgG antibodies
(Sigma-Aldrich, UK), H
2
O
2
, and orthophenylenediamine
(OPD). The reaction was stopped with 0.1M H
2
SO
4
, and
the absorbance read at 492 nm in an ELISA plate reader. All
samples were separately tested and by duplicate, and results
were expressed as mean values. Phage M13K07, MAP46-56,
and E peptide were used as controls in all assays.
2.5. Immunization ofMice. Groups of 10, 4–6 weeks old, male
BALB/c mice (from the Center for Production of Labora-
tory Animals CENPALAB, Havana city Cuba) were injected
intraperitoneally with 50𝜇g of NS4b MAP on days 0, 14,
35, and 56. The antigens were emulsified with, the complete
Freund adjuvant in the first injection and the incomplete
Freund adjuvant in successive ones in a final volume of
0.2mL. Similarly, negative control mice received four doses
of adjuvant alone. Serum samples were obtained from mice
15 days after the last boost and stored at −20∘C until use. All
animal experimentation was carried out in compliance with
the legal requirements of the national authority.
2.6. Serum ELISA to Detect Anti-Peptide Antibodies. Peptide
recognition by anti-peptide antibodies in serum samples
from groups of immunized animals was determined by an
indirect ELISA. Multiwell plates (Nunc Maxisorp F8, Life
Technologies Limited, Paisley) were coated with peptide con-
structs (20𝜇g/mL in 50mM NaHCO
3
, pH 9.6). Plates were
incubated overnight at 4∘C, then washed 3 times with PBS-
T, and blocked with PBS-T/3% bovine serum albumin (BSA)
for 1 h at 37∘C. Serum samples (1/50 dilution in PBS-T/BSA)
from each group were added in duplicate (100 𝜇L/well) and
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incubated 2 h at 37∘C. Plates were washed 3 times with PBS-
T, then incubated for 1 h at 37∘C with 100𝜇L/well of goat
anti-mouse IgG/HRP (Sigma-Aldrich, UK, diluted 1 : 5000),
washed, and developed for 20min with OPD (Sigma, UK).
The reactionwas stoppedwith 100𝜇L of 0.1MH
2
SO
4
, and the
absorbance at 492 nm was recorded by an automated ELISA
reader (Dynex Technologies, UK).
Control ELISAs using the E peptide as capture antigen
were run in parallel. All serum samples were analyzed in
duplicate, and mean values were used for analysis. Each
ELISA was performed twice. Results were expressed as the
ratio of ELISAOD492 nmof immune sera/OD492 nmof pre-
immune sera. A ratio of≥2 with respect to control groups was
chosen as the cutoff value to consider the serum sample as
positive.
Antibody isotypes IgG1 and IgG2a were assayed similarly,
but using pooled sera from each group of mice, diluted 1/50.
The corresponding goat anti-mouse isotype-specific antibody
was used (SIGMA,USA), and the reactivity was revealedwith
HRPO-conjugated rabbit anti-goat IgG antibody (SIGMA,
USA).
2.7. Immunofluorescence Assay (IFA). The Aedes albopictus
cell line (clone C6/36-HT) was grown at 33∘C inMEMmedi-
um containing 2mmol/L glutamine and 10% heat-inactivated
fetal bovine serum (FBS). For the assay, they weremaintained
in the same medium with 2% of FBS.
Viruses. Den-3 116/00 strain with a history of five passages in
C6/36-HT cells (5p C636) and one passage in Vero cells (1p
Vero) was employed at a titer of 1.2 × 105 PFU/mL.
Immunofluorescence Staining. Anti-DEN-3 virus antibodies
in immune sera were detected by indirect immunofluores-
cence. C6/36-HT cells were inoculated with Den-3 116/00 (5p
C636, 1p Vero) (m.o.i.0.01) following the shell vial method
described by Roche et al. [16]. The cells were harvested from
10 h to 48 h postinfection (p. i.), fixed on slides for 20min
in ice cold acetone and incubated with mouse serum diluted
1 : 20 in PBS. Binding of mouse immunoglobulin to cells was
detected using fluorescein-isothiocyanate (FITC) conjugated
goat anti-mouse IgG antibody (Sigma) and examined under
a fluorescence microscope (Leitz Wetzler Germany).
The NS4b-specific polyclonal antiserum was used as a
positive control in all assays. The NS4b protein expressed in
infected cells was detected by immunofluorescence staining
using the NS4b specific polyclonal antiserum at 1 : 20 dilution
in phosphate buffered saline (PBS) as the primary antibody
and FITC-conjugate goat anti-rabbit IgG (Sigma) diluted
1 : 40 in PBS as the secondary antibody.
Pooled serum from preimmune mice was included as
negative control.
All photographs were taken at the same magnification.
2.8. Statistical Analysis. The Mann-Whitney test was used
to compare the results obtained in serum samples from
immunized mice and preimmune sera and was considered
significant if 𝑃 < 0.05.
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Figure 2: ELISA reactivity with NS4b specific polyclonal antiserum
of phage clones 2, 15, and 35 selected from a phage displayed random
peptide library,M13K07wild type control, andNS4bMAP. E peptide
was used as a negative control. The bars represent SDs. The data
represent the average of two separate experiments.
3. Results
3.1. NS4b Mimotope Characterization Using the NS4b-Specif-
ic Polyclonal Antiserum. An NS4b MAP (Figure 1) was
designed according to our previous results [8]. To verify the
antigenic similarity of the phage-displayed peptide andMAP
construct, their capacity to bind to the NS4b specific poly-
clonal antiserum was evaluated in an ELISA. As shown in
Figure 2 the NS4b polyclonal antiserum reacted with all the
phage clones and NS4b MAP. In contrast, the antiserum did
not bind significantly to the control peptides or the con-
trol phage clone M13K07 (Figure 2), showing that NS4b
mimotope exhibits structural similaritywith the dengue virus
epitope.
3.2. Anti-Peptide Antibody Responses and Isotype Distribution
in Immunized Mice. The immunogenicity of the NS4b MAP
was evaluated by measuring peptide specific IgG antibody
levels in serum from immunized mice.The sera were assayed
individually against NS4b MAP as the capture antigen using
an ELISA assay. NS4b MAP induced significant antipeptide
IgG levels (𝑃 < 0.05) (Figure 3). Preimmune sera did not
display ELISA reactivity.
The NS4b-specific IgG2a response was higher than
IgG1 levels indicating a predominantly Th1-type response
(Figure 4).
This assay illustrated that NS4b MAP elicits IgG2a anti-
NS4b MAP antibodies in immunized mice; however it does
not indicate that these would bind infectious DEN-virus.
To determine if these antibodies possess the capacity to
recognize DEN-virus, the antiviral antibody response was
studied.
3.3. Specific Response of Antiserum fromMice Immunized with
NS4b MAP. Induction of an antidengue response by NS4b
MAP at 56 days postimmunization was tested in individual
mice. Specific anti-dengue antibodies were detected by IFA
in sera from mice immunized with the NS4b MAP com-
pared with control sera. Four sera from 5 immunized mice
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Figure 3: Anti-peptide antibody levels elicited by NS4b mimotope
as MAP. Serum samples were obtained on day 0 (preimmune) and
after four injections (day 56) from mice immunized with 50 𝜇g of
antigen (NS4bMAP).The reactivity of each serum was individually
tested, and the average of the results is shown. ELISA plates were
coated with the homologous peptide, and sera were diluted 1 : 50.
Results are expressed as OD ratio and are presented for OD492 nm
(day 56)/OD492 nm (preimmune sera). The cutoff value is an OD
ratio ≥2.0. Antibody levels against NS4b as MAP were significantly
higher (𝑃 < 0.05) than the PBS control.
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Figure 4: IgG1 and IgG2a subclasses induced against NS4b mimo-
tope as MAP after three immunizations (mean from three determi-
nations). Pooled sera from each group of mice (𝑛 = 10) were diluted
1 : 20. Plates were developed using isotype-specific reagents.
reacted with DENV-3 expressed in C636 HT cells, whereas
no immunofluorescence was observed in noninfected cells
(Figure 5(d)). Fluorescent reactivity was not detected in sera
from preimmune mice.
Kinetic expression of viral antigens in infected cells
was also analysed with pooled immune sera. Weak pos-
itive staining was observed in the cytoplasm at 10 h p.i.;
by 12 h the signal became more intense with punctuated
distributionmainly in the perinuclear region of the cytoplasm
(Figure 5(a)). Between 16 h and 20 h postinfection, the
infected cells produced a strong cytoplasmic staining pat-
tern (Figure 5(b)), with the highest intensity at 24 h p.i.
(Figure 5(c)). The intensity of the signal declined from 48 h
p.i.
Anti-NS4b positive control serum detected the expres-
sion ofNS4b protein ofDENV-2 (data not shown) as reported
previously by Miller et al. [10].
4. Discussion
Synthetic peptides derived from mimotopes have been used
to induce specific immune responses against proteins [17].
They have several advantages as immunogens, including
simple antigenic composition, low cost, ease of manufacture,
control of production scale, absence of risk of reversion to
the wild-type, virulent form, and better stability compared
with other vaccine technologies. Presentation of synthetic
peptides as MAPs has been shown to be valuable in vaccine
development [3, 7, 18, 19]; since the increased molecular
weight and repeating peptide structure of MAPs have been
shown to improve immunogenicity [20].
B-cell epitopes have been identified on both structural
and nonstructural dengue proteins including E, NS1, NS4a,
prM, andNS3 [21]. However, the antigenic and immunogenic
characteristics of NS4b protein of dengue virus have been
poorly explored. We have previously identified a DENV-3
phage mimotope with anti-dengue antibodies in human sera;
this mimotope showed partial homology with NS4b dengue
protein (164-171 aa region) [8]. Recently we have demon-
strated that NS4bMAP was recognized by sera from patients
infected with all the serotypes of dengue virus, the highest
reactivity being with sera from DENV-3 infected patients.
In the present study we evaluated the immunogenicity of
NS4b mimotope presented to the immune system as a MAP
construct.
Previously studied dengue phage mimotopes (Ph2, Ph15,
and Ph35) share sequence similarity (FERVPGEVT) and
partial sequence homology (four residues) with amino acids
164–171 of the NS4b dengue protein [8]. This region is highly
conserved among dengue viruses and was described as a
transmembrane domain byMiller et al. [10].The evaluation of
similarities in the physicochemical properties of nonhomolo-
gous amino acid residues could be important in the structural
analysis of linear sequences. Figure 6 shows that the NS4b
mimotope differs from the NS4b sequence by four amino
acids (R166K, V167Q, P168L, and E169Q), and these changed
residues show similarities in the size, polarity, net charge, or
aliphatic character. These physicochemical similarities could
result in the peptide adopting a conformation homologous
with the dengue virus epitope, which would explain the
recognition of the cloned peptides by anti-dengue antibodies,
despite the absence of complete sequence homology with the
original protein.
Antigenic mimicry among the NS4b epitope, phage
mimotopes, and NS4b MAP was determined by binding to
NS4b-specific polyclonal antiserum. Phage mimotopes and
NS4b MAP reacted with the antiserum, reflecting the anti-
genic similarity between the mimotope peptide and NS4 B-
cell epitope. While several studies, including those of our
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Figure 5: Immunofluorescence staining of DEN-infected cells. C636 HT cells were infected with Den-3 116/00 (5p C636, 1p VERO)
(m.o.i.0.01). At 12 (a), 20 (b), and 24 h p.i. (c), the infected cells reacted with individual serum from mice immunized with 50𝜇g of antigen
(NS4b MAP). Non-infected C6/36 HT cells were used as a negative control (d).
laboratory withHAVmimotopes (personal communication),
found that the antigenicity and immunogenicity of a peptide
mimotope can vary by changing the molecular context in
which the peptide is first identified [17], the NS4b mimotope
was still able to bind dengue virus specific antisera and elicit
antibodies binding to dengue virus when removed from the
filamentous phage context, where this mimotope was first
identified.
The ability of peptidemimotopes selected fromphage dis-
played, random peptide libraries to induce specific immune
responses has been reported previously [9, 16, 17]. In this
study a four-armed MAP containing the NS4b mimotope
sequence of DENV-3 was used as immunogen to stimulate
antibodies against dengue virus. The MAP approach has
also been used in the preparation of experimental subunit
vaccines against different pathogens, and hasmultiple advan-
tages [3, 7, 17, 18]. In ours hands, NS4b MAP was immuno-
genic in BALB/c mice, and the elicited antibodies specifically
recognised DENV-3 expressed in cells infected with strain
Den-3 116/00 by immunofluorescence. Although IF against
NS4b dengue 1 
NS4b dengue 2 
NS4b dengue 3 
NS4b dengue 4 
MLLILC 
MLLVLC
MLLVLC
MLLVLC
Phage-displayed peptide Ph2, 15, and 35
FEKQLGQI 
FERVPG V 
FEKQLGQV 
FEKQLGQV 
FEKQLGQV 
...160YDAK
...160YDPK
...159FDSK
...156YDPK
Figure 6: Alignment of the mimotope cloned from phages Ph2, 15,
and 35 with NS4B protein.
the others serotypes was not tested, it is believed that a similar
behaviour could occur, since this small region of NS4b
protein is highly conserved among the four serotypes of den-
gue (Figure 6). Similarly, Tian et al. [9] identified a new con-
servative and continuous epitope of DENV-2 NS3 protein
using a phage-displayed peptide library and demonstrated its
potential application in the design of an epitope vaccine to
prevent dengue infection.
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It is interesting to note that topological studies of NS4B
show that the sequence homologous with the mimotope (aa
164–171) seems to reside in the transmembrane region of
the endoplasmic reticulum [10]. Our results indicate that
the NS4b epitope could be accessible for binding to B-cell
receptors during cell lysis induced by the virus or immune
cell mediated lysis [22]. Another explanation could be that
dendritic cells, monocytes/macrophages, and B cells are
target cells for dengue virus, and NS4b protein produced
in the cytoplasm of these infected cells during the cycle of
replication could be degraded into peptides that enter in the
class II MHC pathways of antigenic presentation.
The kinetic expression of dengue NS4b protein has previ-
ously been studied in infected cells [10]. We detected the
protein from 10 h postinfection using pooled sera from mice
at 56 days postimmunization, and similar results were
observed with the antiNS4b specific polyclonal antiserum.
These results suggest that the antibodies elicited by NS4b
mimotope are able to recognize NS4b protein, which is
produced in the first step of viral replication.
T-cell responses were studied by measuring IgG subclass
composition of sera from immunizedmice.The highest levels
of the anti-NS4b IgG2a subtype suggests the induction of
a Th1-like response. A Th1 response with the expression of
IgG2a would be desirable, as this murine isotype has been
reported to be particularly effective for virus clearance. Fur-
thermore, Th1 cells may contribute to protection against den-
gue by upregulating the cytotoxic response to destroy virus
infected cells early in infection [23]. The signature cytokine
of Th1 cells is INF𝛾 the most potent macrophage-activating
cytokine in the immune system. This cytokine has been
described as a mediator of the cellular immune response
and plays a role in the antiviral activity against DENV [24].
Further studies are needed to determine the secretion of this
cytokine by stimulated CD4+ and CD8+ T cells from mice
immunized with NS4b MAP.
The antibody response generated by NS4b MAP could
indicate the presence of both T and B epitopes in the region
amino acids 164–171 of the NS4b dengue protein sequence.
5. Conclusions
In the present study, we evaluated the antigenicity and immu-
nogenicity of a NS4b dengue virus mimotope. The MAP
construct containing four arms of this mimotope induced
anti-peptide antibodies that specifically recognised DENV-
3 expressed in infected cells. Our results suggest that the
NS4b peptide could be included as part of an experimental
antidengue subunit vaccine. These findings also suggest that
the NS4b protein of dengue virus could be implicated in the
humoral response.
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